Dosing & Uses
Dosage Forms & Strengths
tablet
- 500mg
HIV Infection
1000 mg (with ritonavir 100 mg) PO q12hr, or in combination with ritonavir-enhanced lopinavir
Treatment-naïve patients
- Initial dose: 500 mg PO BID plus ritonavir 100 mg BID x 7 days, THEN increase to 1000mg/100mg PO BID
- This gradual increase is due to potential for increased risk of PR and QT interval prolongation with standard 1000/100-mg BID dose
- Patients with a baseline QT interval <450 msec, an on-treatment ECG is recommended after ~10 days of therapy
- Patients with a QT interval prolongation over pretreatment by >20 msec should discontinue saquinavir/ritonavir therapy
Dosage Forms & Strengths
tablet
- 500mg
HIV Infection
Indicated in combination with ritonavir and other antiretrovirals (ARTs) for treatment of HIV-1 infection
<16 years: Safety and efficacy not established
≥16 years: 1000 mg (plus ritonavir 100 mg) PO q12hr
For patients already taking ritonavir 100 mg BID as part of their ART regimen, no additional ritonavir is needed
Treatment-naïve patients
- Initial dose: 500 mg PO BID plus ritonavir 100 mg BID x 7 days, THEN increase to 1000mg/100mg PO BID
- This gradual increase is due to potential for increased risk of PR and QT interval prolongation with standard 1000/100-mg BID dose
- Patients with a baseline QT interval <450 msec, an on-treatment ECG is recommended after ~10 days of therapy
- Patients with a QT interval prolongation over pretreatment by >20 msec should discontinue saquinavir/ritonavir therapy
Investigational in treatment-experienced children
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
1-10%
Rash
Hyperglycemia
Diarrhea
Abdominal discomfort
Nausea
Abdominal pain
Buccal mucosa ulceration
Paresthesia
Weakness
Increased CPK
<1%
Headache
Confusion
Seizures
Ataxia
Pain
Stevens-Johnson syndrome
Hypoglycemia
Hyper- & hypokalemia
Low serum amylase
AML
Hemolytic anemia
Thrombocytopenia
Jaundice
Ascites
Warnings
Black Box Warnings
Saquinavir mesylate (Invirase) capsules and tablets, and saquinavir (Fortovase) soft gelatin capsules, are not bioequivalent and cannot be used interchangeably
Fortovase is no longer available in the United States
Use saquinavir mesylate (Invirase) only if it is combined with ritonavir, which significantly inhibits saquinavir's metabolism to provide plasma saquinavir levels at least equal to those achieved with saquinavir (Fortovase)
Contraindications
Hypersensitivity (eg, anaphylactic reaction, Stevens-Johnson syndrome)
An ECG should be performed prior to initiation of treatment; patients with a QT interval = 450 msec should not initiate therapy
Treatment-naïve patients initiating therapy should receive a reduced starting dose of saquinavir 500-mg twice daily with ritonavir 100-mg twice daily for the first 7 days of treatment followed by saquinavir/ritonavir 1000/100 mg twice daily due to potential for an increased risk of PR and QT interval prolongation with the standard 1000/100-mg twice daily dose
QT and PR interval prolonation and torsades de pointes have been reported rarely; do not use saquinavir/ritonavir with congenital or documented acquired QT prolongation (≥450 msec), refractory hypokalemia or magnesemia, and in combination with drugs that prolong QT interval
Complete atrioventricular (AV) block without implanted pacemakers or high risk of complete AV block
Severe hepatic impairment
Coadministration of saquinavir/ritonavir with rifampin due to the risk of severe hepatotoxicity
Drugs that are contraindicated with saquinavir (when coadministered 'boosted' with ritonavir) include CYP3A inhibitors that may result in increased saquinavir plasma levels and cause serious or life-threatening reactions (eg, prolonged QT interval)
Drug contraindicated with saquinavir/ritonavir include alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine, lidocaine), trazodone, rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, HMG-CoA reductase inhibitors (lovastatin, simvastatin), lurasidone, pimozide, clarithromycin, erythromycin, halofantrine, pentamidine, clozapine, haloperidol, sertindole, ziprasidone, atazanavir, tacrolimus, rilpivirine, dasatinib, sunitinib, disopyramide, quinine, phenothiazines (e.g. chlorpromazine, mesoridazine, thioridazine), sildenafil (when used for PAH), midazolam, and triazolam
Cautions
Hyperlipidemia may occur
Take within 2 hr after meal; absorption increased with high-fat meal
Must be used in combination with ritonavir (ie, boosted therapy) to achieve necessary levels for effectiveness
Autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) reported in the setting of immune reconstitution; however, time to onset is variable, and can occur many months after treatment initiation
Risk of QT and PR prolongation that might lead to Torsades de Pointes (particularly if used with ritonavir); discontinue therapy if significant arrhythmias, QT or PR prolongation occurs; perform ECG prior to initiation of treatment; patients with a baseline QT interval < 450 msec, an on-treatment ECG is recommended after approximately 10 days of therapy; patients with a QT interval prolongation over pre-treatment by > 20 msec should discontinue saquinavir/ritonavir therapy
May develop new onset or exacerbations of diabetes mellitus, hyperglycemia, elevated cholesterol and/or triglyceride concentrations, redistribution/accumulation of body fat, and immune reconstitution syndrome; monitor cholesterol and triglycerides prior to therapy and periodically thereafter
In patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism or other underlying liver abnormalities, worsening of underlying liver disease and development of portal hypertension reported after initiating therapy; jaundice and exacerbation of chronic liver disease with grade 4 elevated liver function tests also observed; no dosage adjustment necessary for patients with mild or moderate hepatic impairment based on limited data; saquinavir/ritonavir contraindicated in patients with severe hepatic impairment; if a serious or severe toxicity occurs during treatment, discontinue therapy
Spontaneous bleeding may occur and additional factor VII may be required
Various degrees of cross-resistance have been observed
Not recommended for use in combination with cobicistat
Tablets and capsules contain lactose; not recommended in patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose or malabsorption
Pregnancy & Lactation
Pregnancy
There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to antiretrovirals during pregnancy; healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263
Prospective pregnancy data from the APR are not sufficient to adequately assess a drug-associated risk of birth defects or fetal outcomes; limited number of reports on use of drug during pregnancy has been submitted to the APR and number of exposures to drug is insufficient to make a risk assessment compared to a reference population
Animal data
- In animal reproduction studies with saquinavir, no evidence of adverse developmental effects were observed at highest achievable plasma exposures (AUC) in both rats and rabbits, resulting in exposures approximately 25% of those obtained in humans at recommended human dose (RHD) combined with drug; therapy should be administered during pregnancy only if potential benefit justifies potential risk to fetus
Lactation
The Centers for Disease Control and Prevention recommends that HIV-infected mothers in US not breastfeed their infants to avoid risking postnatal transmission of HIV-1
There are no data available regarding presence of drug in human milk, effects on breastfed infant, or on milk production
Because of potential for HIV-1 transmission (in HIV-negative infants), developing viral resistance (in HIV-positive infants) and adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed if receiving therapy
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Protease Inhibitor; inhibits cleavage of Gag-Pol polyprotein precursors, which in turn causes the formation of immature, noninfectious viral particles.
Combination (boosted therapy) use recommended
Absorption
Poor absorption; increased with high fat meal
Protein Bound: ~98%
Distribution
Does not distribute into CSF
Vd: 700 L
Metabolism
Extensively metabolized via hepatic CYP3A4; extensive first-pass effect
Elimination
Excretion: Fece: 81-88%; urine: 1-3%
Administration
Oral Administration
Saquinavir plus ritonavir should be taken with 2 hr after a meal
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.